- MedMira Inc. (MIR) launches its Reveal® TP product in Europe and commenced clinical trials in Canada
- The company received the CE mark today making it available in Europe and any countries accepting the CE mark
- Its planned clinical trial in Canada will start in the spring with REACH Nexus’ help
- REACH Nexus is a national research group working on how to address HIV, Hepatitis C, and other sexually transmitted and blood-borne infections
- Work will begin in Saskatchewan for a study to address the syphilis outbreaks there using the Reveal® TP Product
- MedMira Inc. (MIR) is unchanged trading at $0.12 per share as of 1:54 p.m. EST
MedMira Inc. (MIR) has introduced its Reveal® TP product in Europe and commenced clinical trials in Canada.
The company received the CE mark today making it available in Europe and any countries accepting the CE mark.
MedMira continues its work on the Investigational Testing Application for its planned clinical trial in Canada to start in the spring with the support and partnership of REACH Nexus at the MAP Centre for Urban Health Solutions in St. Michael’s Hospital of Unity Health Toronto.
REACH Nexus is a national research group working on how to address HIV, Hepatitis C, and other sexually transmitted and blood-borne infections in Canada. Its focus is on reaching the undiagnosed, implementing and scaling up new testing options, strengthening connections to care, improving access to options for prevention and ending stigma.
The team at REACH Nexus is leading efforts to address these epidemics by working collaboratively with Canadian diagnostic developers, health care providers, community stakeholders and people with lived experience, researchers, health ministries and public health to bring new POC tests to market here in Canada.
Using this novel implementation science approach, the work is progressing well in northern Alberta to “test and treat” for HIV and syphilis while evaluating the performance of the Multiplo®, an HIV and syphilis POC test made by MedMira.
Later this spring, work will begin in Saskatchewan to conduct another “test and treat” study to address the syphilis outbreaks there using the Reveal® TP Product while also collecting performance data which MedMira will use for their licensing application to Health Canada.
MedMira along with their partners from REACH Nexus have identified clinical and community sites in the Western part of Canada as an ideal location for this next “test and treat” clinical trial and implementation science study, subject to Health Canada’s authorization.
MedMira Inc. (MIR) is unchanged trading at $0.12 per share as of 1:54 p.m. EST.